KEYNOTE-522: Neoadjuvant KEYTRUDA® (pembrolizumab) plus chemotherapy followed by adjuvant pembrolizumab monotherapy in patients with triple-negative breast cancer (TNBC)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 03:45
The KEYNOTE-522 Data animation provides an overview of the primary end points, efficacy, and safety data from the KEYNOTE-522 clinical trial “Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer”. Presented by principal investigator Professor Peter Schmid.
KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.1
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.1
Please consult SmPC before making any prescribing decisions.
More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)
Reference
- KEYTRUDA Summary of Product Characteristics
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
